Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore Mirion’s deepening foothold in the secularly growing nuclear sector and its ability to translate acquisitions and AI‑driven efficiencies into higher margins and cash generation, positioning the company for accelerated growth in 2026.

Key Takeaways

• Record $1.1B orders, 26% YoY increase.
• Nuclear power now 40% of revenue after acquisitions.
• 2026 revenue forecast 22‑24% growth, organic 5‑7%.
• Adjusted EBITDA margin target 25‑26% with 90bps expansion.
• AI and procurement synergies drive margin improvement.

Pulse Analysis

Mirion Technologies’ 2025 performance highlights the accelerating demand for nuclear‑power services as utilities scramble to replace aging capacity and meet climate goals. The company’s installed‑base model, which now generates roughly 80% of revenue from upgrades and life‑extension projects, provided a stable cash flow foundation while large‑project bookings surged past $400 million. This secular tailwind, combined with a 13% organic rise in nuclear‑medicine revenue, positions Mirion as a key supplier across the entire reactor lifecycle, from fuel‑cycle support to decommissioning.

Strategic acquisitions have been central to Mirion’s growth narrative. The integration of CertRec’s regulatory‑compliance SaaS platform and Paragon Energy Solutions’ North‑American nuclear‑power portfolio not only lifted nuclear‑power exposure to about 40% of total sales but also opened cross‑selling opportunities in the emerging small modular reactor (SMR) market. With more than 20 SMR developers now in its ecosystem, Mirion can capture licensing, instrumentation, and data‑analytics contracts that are expected to expand from sub‑2% to sub‑3% of revenue in 2026. Concurrently, the rollout of 17 internal AI applications and ongoing procurement optimization delivered nearly 100 basis points of margin improvement, illustrating how digital tools are becoming a lever for profitability.

Looking ahead, Mirion’s 2026 guidance signals a robust growth trajectory. Revenue is projected to climb 22‑24%—including FX and acquisition effects—while organic growth alone should reach 5‑7%, reflecting continued nuclear‑power and medical demand. The company also expects adjusted EBITDA margins of 25‑26% and free‑cash‑flow generation of $155‑175 million, supported by a restructured term loan that cut borrowing costs to 2.9%. For investors, the blend of secular market tailwinds, disciplined capital‑structure management, and margin‑enhancing AI initiatives suggests a compelling upside narrative as the firm scales its nuclear and safety solutions globally.